News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Ocular Therapeutix, Inc. Adds $6 Million to C Round
January 13, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Xconomy -- Ocular Therapeutix, a Bedford, MA-based developer of therapies for the eye, has brought in an additional $6 million for its Series C round, which now totals $21 million, company co-founder and CEO Amar Sawhney confirmed via e-mail today.
Twitter
LinkedIn
Facebook
Email
Print
Startups
MORE ON THIS TOPIC
Layoff Tracker
Concerto Downsizes Amid Pivot to Consumers; Faraday Closes Down
February 18, 2026
·
55 min read
·
BioSpace Editorial Staff
Podcast
Modernagate Fallout, Disc’s Rejection, Compass’ Psilocybin Data, CDC’s Lost Leaders
February 18, 2026
·
1 min read
·
Heather McKenzie
Opinion
Biopharma Must Cope With The Fetal Bovine Serum Squeeze
February 17, 2026
·
5 min read
·
Tom Kutrubes
Manufacturing
Radiopharma Sector Races To Secure Actinium-225 Supply as Pipelines Expand
February 17, 2026
·
4 min read
·
Nick Paul Taylor